This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
Dutch inflammation specialist Citryll BV has raised €85m to push clininal testing of its lead candidate, CIT-013, a bifunctional antibody that prevents the release of neutrophil extracellular traps (NETs) from neutrophil granulocytes into the cytoplasm, thus blocking inflammatory and autoimmune diseases at its very roots.
Dewpoint Therapeutics Inc and Mitsubishi Tanabe Pharma Corporation have formed a collaboration, valued at up to $480m, to develop a novel small molecule condensate modulator for ALS, leveraging groundbreaking European research in condensate biology.
The British NICE has defined the conditions for the reimbursement of Eli Lilly’s obesity blockbuster tirzepatide. This makes the UK the first country in which patients do not have to pay for the drug out of their own pocket.
French Ipsen has exclusively licensed BMX-502, a T-cell engager (TCE) from Biommunex SA, which prevents common problems of TCEs such as cytokine release syndrome and T cell exhaustion by using a specific mucosal T cell subpopulation abundant in the human body.
After securing an equity investment from French pharma giant Sanofi, Italian gene therapy company Resalis Therapeutics srl has begun enrolling participants for a Phase I study of its obesity gene therapy, RES-010, which converts white adipocytes into brown adipocytes.
The Society for Laboratory Automation & Screening (SLAS) has selected the European Biotechnology Magazine as its official media partner.
Chinese researchers headed by Prof. Dr. Hongbing Deng from Wuhan University report they were able to absorb up to 99.9% of microplastics in water, which could help solve one of the most pressing environmental problems.
The Dutch-Swiss company with operations also in Zurich, Switzerland, has raised US$73m in a Series B and will continue to expand its AI research, sales, and operations teams. The new announcement comes around a year after raising €21.92m in a Series A funding round.
Genentech, the US arm of Swiss-based Roche AG, plans to acquire its long-time partner in allogeneic CAR-T blood cancer and gene therapies, Poseida Therapeutics Inc, for up to US$1.5bn.
The General Court of the EU orders the European Commission to pay the costs in the case of Aplidin® against the Spanish company PharmaMar SA, in which an EU marketing authorisation was not granted due to conflict-of-interests within the CHMP of the European Medicines Agency.